Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jupiter Neurosciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
JUNS
Nasdaq
2834
jupiterneurosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jupiter Neurosciences, Inc.
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
- Feb 4th, 2025 2:25 pm
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
- Feb 3rd, 2025 1:00 pm
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
- Jan 30th, 2025 1:00 pm
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
- Jan 13th, 2025 1:00 pm
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
- Dec 4th, 2024 9:56 pm
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
- Dec 3rd, 2024 12:00 am
Scroll